Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00268294
Other study ID # 221
Secondary ID
Status Completed
Phase N/A
First received December 21, 2005
Last updated December 16, 2008
Start date May 2003
Est. completion date April 2006

Study information

Verified date December 2008
Source Medtronic Cardiac Rhythm Disease Management
Contact n/a
Is FDA regulated No
Health authority Germany-Competent Authority: Bezirksregierung Dusseldorf
Study type Interventional

Clinical Trial Summary

Heart failure is a progressive disease that decreases the pumping action of the heart. This may cause a backup of fluid in the heart and may result in heart beat changes. When there are changes in the heart beat sometimes an implantable heart device is used to control the rate and rhythm of the heart beat. In certain heart failure cases, when the two lower chambers of the heart no longer beat in a coordinated manner, cardiac resynchronization therapy may be prescribed.

People who have a dangerously fast heart beat, or whose heart is at risk of stopping beating, may be in need of an electronic device called an implantable cardioverter defibrillator (ICD).

Atrial tachyarrhythmia (AT) is the name for rapid beats in the upper chambers of the heart. People with AT may experience symptoms such as heart palpitations (a racing or pounding feeling in the chest), shortness of breath, dizziness, fatigue or weakness.

The purpose of this study is to characterize the impact of cardiac resynchronization therapy versus cardiac resynchronization therapy with atrial therapies on the incidence, duration and termination of atrial tachyarrhythmias.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date April 2006
Est. primary completion date April 2006
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subjects with atrial fibrillation

- Subjects with a heart beat that is too fast and who have been determined by a doctor to require an implantable cardioverter defibrillator (ICD) i.

Exclusion Criteria:

- Subjects with a natural heart rate less than 30bpm

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Cardiac Resynchronization Therapy


Locations

Country Name City State
Germany Zentralklinik Bad Berka GmbH Bad Berka

Sponsors (2)

Lead Sponsor Collaborator
Medtronic Cardiac Rhythm Disease Management Medtronic

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary To compare the AF burden, frequency and duration of episodes when atrial therapies are ON vs. OFF.